PEPG News & Events

Stocks rallied early in session on Wednesday and then sustained their gains while the fear-gauge Vix index retreated from the 24-handle to a low-20 as investors appear to be growing less nervous around the prospects of a protracted conflict in the Middle East.  Traders snapped up the beaten-down Tech names - especially Memory, with Micronup a strong 5.5%.  Large-cap Consumer Cyclicals also traded notably firmer, as Amazonand Teslapaced the group with gains of over 3%.  Crypto stocks were likewise notably higher - Coinbasewas one of the S&P 500's best performing names, gaining 15%, and Robinhoodfollowed closely with an 8% rally.  In turn, Energy stocks sagged, even though Crude Oil remains above $75 per barrel.In the opening hour of the evening session, S&P 500 e-minis and Nasdaq 100 futures are up 0.3% and 0.4% respectively.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER AFTER EARNINGS -Veeva Systemsup 10.9%Oomaup 10.9%Cracker Barrelup 6.6%Broadcomup 5.0%Oktaup 1.9%ALSO HIGHER -The Trade Deskup 9.1% after OpenAI ad partnership reportGraphic Packaging Holdingup 5.9% after insider buyDOWN AFTER EARNINGS -Grocery Outletdown 21.4%PepGendown 17.1%StubHub Holdingsdown 9.5%American Eagledown 2.1%ALSO LOWER -IREN Limiteddown 5.3% after purchase agreements for over 50,000 Nvidia B300 GPUs

PepGen announced regulatory updates related to the Freedom2 trial. The U.S. Food and Drug Administration has placed a partial clinical hold on the Freedom2-DM1 Phase 2 multiple ascending dose, randomized, placebo-controlled clinical trial of PGN-EDODM1 in patients with myotonic dystrophy type 1. The partial clinical hold questions raised by FDA relate to previously submitted preclinical pharmacology and toxicology studies. The partial clinical hold did not cite any questions regarding blinded clinical data from the Phase 1 Freedom study previously submitted to the FDA in order to initiate the Freedom2 study in the U.S. As part of its ongoing dialogue with the FDA, the Company is submitting additional analyses, including the recently unblinded Freedom data, and is committed to working with the FDA to address their questions as quickly as possible. PepGen was recently cleared to open the Freedom2 study in New Zealand, Australia, and South Korea. The Company expects to report data from the 5 mg/kg cohort of Freedom2 in the first quarter of 2026, and from the 10 mg/kg cohort in the second half of 2026.

"2025 was a transformative year for PepGen as the Phase 1 FREEDOM trial delivered compelling data that set a new benchmark for splicing correction in DM1, reinforced our conviction in PGN-EDODM1 as a potential best-in-class treatment, and further demonstrated the differentiated potential of our EDO platform," said James McArthur, PhD, President and Chief Executive Officer of PepGen. "After a single dose, we observed robust target engagement beginning at the lowest dose of 5 mg/kg - a finding that exceeded our expectations and underscored the potency of our drug candidate. PGN-EDODM1 was generally well-tolerated across doses, and based on the totality of FREEDOM data, we believe that doses of 10 mg/kg could potentially offer a best-in-class treatment option for people living with this serious disease."